251 286 - Biotech Bayern
251 286 - Biotech Bayern
251 286 - Biotech Bayern
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Contact:<br />
Rachela Mohr<br />
Hanns-Seidel-Platz 4<br />
D-81737 München<br />
Phone: +49 (0) 89 6279-0<br />
Fax: +49 (0) 89 6279-1770<br />
E-Mail: info@wacker.com<br />
Internet: www.wacker.com<br />
Contact:<br />
Juliane Giese<br />
Grillparzerstr. 10<br />
D-81675 München<br />
Phone: +49 (0) 89 41 31 38-0<br />
Fax: +49 (0) 89 41 31 38-99<br />
E-Mail: info@wilex.com<br />
Internet: www.wilex.com<br />
112<br />
Wacker Chemie AG<br />
PHARMA & CHEMICAL INDUSTRY<br />
WACKER is a globally active chemical company headquartered in Munich,<br />
Germany. With a wide range of state-of-the-art specialty products, WACKER is<br />
a leader in numerous industrial sectors. Its products are required in countless<br />
high-growth end-user sectors such as photovoltaics, electronics, pharmaceuticals<br />
and household/personal care products.<br />
WACKER's operations are divided among following business divisions:<br />
WACKER SILICONES, WACKER POLYMERS, WACKER FINE CHEMICALS, WACKER<br />
POLYSILICON and SILTRONIC. The Group operates 22 production sites worldwide,<br />
supplying over 3,500 products to more than 3,500 customers in over 100 nations.<br />
The company is represented by subsidiaries and sales offices in over 28 countries<br />
across Europe, the Americas and Asia – including a strong foothold in China.<br />
Wilex AG<br />
BIOTECH THERAPEUTICS & DIAGNOSTICS<br />
Keywords: Drug Development, Antibody, Small Molecules<br />
WILEX is a biopharmaceutical Company based in Munich founded in 1997 by a<br />
team of physicians and oncologists from the Technical University of Munich.<br />
WILEX is focused on the development of new cancer therapies based on antibodies<br />
and small molecules. The therapeutic approach of WILEX targets the<br />
prevention of growth, spread and the metastasis of malignant tumours and the<br />
destruction of malignant tumours in the body. The late stage multi-product<br />
portfolio includes both, drug and medicinal product candidates as well as<br />
research candidates. Currently the following compounds are in clinical development:<br />
WX-G250 (development name: RENCAREX®), WX-671, WX-UK1 and<br />
CA9-SCAN. The company’s strategy is to develop WILEX into a commercially<br />
successful biopharmaceutical company with a broad portfolio of new drugs and<br />
medical products for the treatment of cancer. WILEX AG has been listed in the<br />
Official Market Segment (Amtlicher Markt) / Prime Standard of the Frankfurt<br />
Stock Exchange since 13 November 2006.
Change language